Crossmark Global Holdings Inc. Acquires 20,055 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crossmark Global Holdings Inc. boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 57.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,689 shares of the company’s stock after purchasing an additional 20,055 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Takeda Pharmaceutical were worth $778,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares during the period. Headlands Technologies LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter valued at approximately $59,000. Hexagon Capital Partners LLC increased its stake in shares of Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock worth $63,000 after purchasing an additional 1,129 shares during the period. Blue Trust Inc. lifted its holdings in Takeda Pharmaceutical by 74.0% during the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after purchasing an additional 2,330 shares during the last quarter. Finally, Ridgewood Investments LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter valued at $89,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.4 %

TAK stock opened at $13.62 on Friday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The stock has a market capitalization of $43.34 billion, a price-to-earnings ratio of 23.33, a PEG ratio of 0.26 and a beta of 0.54. The business’s fifty day moving average price is $14.27 and its two-hundred day moving average price is $13.82.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.